Drug Profile
Research programme: antiviral therapeutics - AbbVie/Intellectual Dialog
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Abbott Laboratories
- Developer AbbVie; Intellectual Dialog
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Viral infections
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Viral-infections(In children, In the elderly) in Russia
- 02 Jan 2013 Abbott separates its pharmaceuticals business to new company called AbbVie
- 09 Jul 2012 Early research in Viral infections in Russia (unspecified route)